Tumor-Agnostic Therapies and the Future of HER2 in Oncology

Labcorp, Rebecca Previs, Heidi Ko, HER2, NGS, precision oncology, tumor agnostic, breast cancer, gastric cancer, biomarker, ERBB2, IHC, FISH, biomarker

What tumor-agnostic approvals mean for HER2, NGS, and precision oncology — and how they’re changing treatment across cancer types.

Jun 8^th • 20 mins listen

Redefining Ovarian Cancer Care with Biomarkers

Labcorp, Rebecca Previs, Kyle Strickland, ovarian cancer, diagnosis, biomarker, HRD, RB1, tumor biology

Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology.

Sep 7^th • 14 mins listen

How Team Science is Driving Lung Cancer Breakthroughs

City of Hope, Monty Pal, Loretta Erhunmwunsee, lung cancer, thoracic surgeon, air pollution, diversity

Dr. Loretta Erhunmwunsee explores her latest groundbreaking research investigating the impact of air pollution on lung cancer and shares how team science is critical to advancing cancer care for all.

Aug 19^th • 32 mins listen